Meeting
2011 ASCO Annual Meeting
Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial.
Authors
K. Shen
Precision Therapeutics, Inc., Pittsburgh, PA
K. Shen , G. Tang , J. P. Costantino , S. J. Anderson , C. Kim , K. L. Pogue-Geile , N. Song , M. J. Gabrin , C. E. Geyer , N. Wolmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT00002707
Citation
J Clin Oncol 29: 2011 (suppl; abstr 1029)
Abstract #
1029
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2021 ASCO Annual Meeting
Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.
First Author: Douglas W. Blayney
Poster
2021 ASCO Annual Meeting
Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).
First Author: Yuankai Shi
Poster
2018 ASCO Annual Meeting
Artificial intelligence methods to predict chemotherapy-induced neutropenia in breast cancer patients.
First Author: Peter Abdul DeWan